Department of Nephrology, Klinikum Stuttgart - Katharinenhospital, Stuttgart, Germany.
Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany.
Int J Immunogenet. 2021 Apr;48(2):201-210. doi: 10.1111/iji.12512. Epub 2020 Sep 17.
Due to a widespread organ shortage, the use of expanded criteria donors (ECDs) in kidney transplantation has increased persistently, reaching approximately 40% in recent years. Whether human leucocyte antigen (HLA) matching between donor and recipient should be part of allocation algorithms in transplantation of ECD kidneys, and especially of ECD kidneys from ≥70-year-old donors, is still in question. To this end, 135,529 kidney transplantations performed between 2000 and 2017 and reported to the Collaborative Transplant Study were analysed and the impact of HLA-A+B+DR mismatches on death-censored graft and patient survival as well as on rejection episodes was investigated. Results were stratified according to donor status (standard criteria donor (SCD) versus ECD) and age of ECD. HLA incompatibility increased the five-year death-censored graft failure risk similarly strong in recipients of ECD and SCD transplants (hazard ratio (HR) per HLA mismatch 1.078 and 1.075, respectively; p < .001 for both). Its impact on rejection treatments during the first post-transplant year was also significant but slightly weaker for recipients of ECD transplants (risk ratio (RR) per HLA mismatch 1.10 for ECD transplants and 1.13 for SCD transplants; p < .001 for both). Mortality increased gradually from zero to six HLA mismatches in recipients of SCD transplants, whereas for ECD transplants a significant increase was notable only from zero to more than zero mismatches. A significant but slightly less pronounced impact of HLA incompatibility on graft failure was observed in transplants from ≥70- compared with <70-year-old ECDs (HR per mismatch 1.047 and 1.093; p = .009 and < 0.001, respectively). The influence of HLA mismatches on rejection treatments was the same for both ECD age groups (RR = 1.10, p < .001 and p = .004, respectively). Our data indicate that HLA matching should be part of allocation algorithms not only in transplantation of kidneys from SCDs but also from ECDs.
由于器官广泛短缺,在肾移植中使用扩展标准供者(ECD)的情况持续增加,近年来达到约 40%。在移植 ECD 肾脏,特别是移植≥70 岁 ECD 肾脏时,供者和受者之间的人类白细胞抗原(HLA)匹配是否应作为分配算法的一部分,仍存在争议。为此,分析了 2000 年至 2017 年期间向协作移植研究报告的 135529 例肾移植,并研究了 HLA-A+B+DR 错配对死亡风险校正移植物和患者存活率以及排斥反应的影响。结果根据供者状态(标准供者(SCD)与 ECD)和 ECD 年龄进行分层。在接受 ECD 和 SCD 移植的受者中,HLA 不匹配同样强烈地增加了五年死亡风险校正移植物失败的风险(每一个 HLA 错配的风险比(HR)分别为 1.078 和 1.075;两者均<0.001)。它对移植后第一年排斥反应治疗的影响也很显著,但对于接受 ECD 移植的受者则稍弱(每一个 HLA 错配的风险比(RR)分别为 1.10 和 1.13;两者均<0.001)。在接受 SCD 移植的受者中,死亡率从无 HLA 错配逐渐增加到 6 个 HLA 错配,而在接受 ECD 移植的受者中,只有从无错配增加到有 HLA 错配时才会显著增加。在移植来自≥70 岁 ECD 与<70 岁 ECD 患者时,HLA 不匹配对移植物失败的影响有显著但略弱的影响(每一个错配的 HR 分别为 1.047 和 1.093;p=0.009 和<0.001)。HLA 错配对排斥反应治疗的影响在两个 ECD 年龄组中相同(RR=1.10,p<0.001 和 p=0.004)。我们的数据表明,HLA 匹配不仅应作为 SCD 肾脏移植,也应作为 ECD 肾脏移植分配算法的一部分。